- Sangamo spent three years building their genomic medicines platform, pipeline and in-house manufacturing capabilities while saying they were not interested in being acquired.
- The pipeline is not broad and deep with lead assets poised to validate the underlying platforms.
- Several of the largest pharmaceutical companies curbed spending on neuroscience. That trend is reversing rapidly.
- At the December Truist Virtual Conference, Sangamo said they were open to being acquired.
- When this article was written the share price as $13. When it was submitted the price was $15.
For further details see:
Sangamo: 'Good Companies Get Bought, Not Sold'